Special lssues
Table of Content

PD-1 in Cancer Therapy

Submission Deadline: 31 December 2024 Submit to Special Issue

Guest Editors

Prof. Xuelei Ma
West China School of Medicine/West China Hospital of Sichuan University, China

Prof. Mohamad Saifudin Hakim
Department of Microbiology, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Indonesia
Erasmus MC-University Medical Center Rotterdam, The Netherlands


The discovery of the programmed cell death protein 1 (PD-1) and its ligand (PD-L1) has marked a pivotal milestone in cancer research over the past two decades. The PD-1/PD-L1 pathway's role in regulating T cell function and its exploitation by tumors for immune escape have spurred the development of groundbreaking immunotherapies. Monoclonal antibodies targeting PD-1 or PD-L1, such as nivolumab, pembrolizumab, and atezolizumab, have demonstrated significant clinical benefits, reshaping the landscape of cancer treatment. Despite these successes, challenges persist, prompting a deeper exploration into the complexities of the PD-1/PD-L1 blockade and the quest for innovative strategies to overcome resistance.This special issue aims to provide a comprehensive platform for the discussion of recent advances in the efficacy and safety profiles of PD-1/PD-L1 blockade in cancer treatment. We seek to unravel the intricacies of this immune checkpoint pathway, from its historical development to the latest breakthroughs in research.


Key Focus Areas:

Investigate tumor resistance to anti-PD-1/PD-L1 therapy;

Explore the role of alternative inhibitory immune checkpoints in overcoming resistance;

Emerging strategies, such as oncolytic virus immunotherapy and gene therapies, to enhance anti-tumor immune responses.


PD-1; Cancer Therapy; immunotherapy

Share Link